Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric...

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Antibody-mediated rejection (AMR) is a primary cause of early kidney allograft loss.
• Standardized methods for antibody measurement, therapy, and endpoints in AMR are lacking.
• Donor-specific antibodies (DSA) play a critical role in AMR.

Purpose of the Study:

• To evaluate the effectiveness of risk stratification using systematic donor-specific antibody (DSA) monitoring in pediatric kidney transplant recipients.
• To determine if C1q-binding DSA (C1q-dnDSA) is a reliable noninvasive biomarker for predicting graft failure.

Main Methods:

• Retrospective analysis of 233 pediatric kidney transplant recipients from January 2010 to March 2018.
• Systematic monitoring of donor-specific antibodies (DSA), including C1q-binding DSA (C1q-dnDSA).
• Assessment of graft failure rates and association with C1q-dnDSA status following an augmented immunosuppressive protocol.

Main Results:

• Fifty-two patients (22%) developed C1q-dnDSA; 58.5% of these resolved after intensified immunosuppression.
• Graft failure occurred in 16 patients, with 14 having DSA; all 14 rejected grafts had persistent C1q-dnDSA.
• Persistent C1q-dnDSA demonstrated the strongest independent association with graft failure (HR, 45.5).

Conclusions:

• C1q-binding DSA monitoring is a valuable tool for risk stratification in pediatric kidney transplantation.
• Persistent C1q-dnDSA is a potent noninvasive biomarker for identifying patients at high risk of graft failure due to rejection.
• This monitoring strategy can aid in timely therapeutic interventions to prevent allograft loss.